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Abstract
Background: Current research suggests that a small set of “driver” mutations are responsible for
tumorigenesis while a larger body of “passenger” mutations occurs in the tumor but does not progress
the disease. Due to recent pharmacological successes in treating cancers caused by driver mutations, a
variety of of methodologies that attempt to identify such mutations have been developed. Based on the
hypothesis that driver mutations tend to cluster in key regions of the protein, the development of cluster
identification algorithms has become critical.
Results: We have developed a novel methodology, SpacePAC (Spatial Protein Amino acid Clustering),
that identifies mutational clustering by considering the protein tertiary structure directly in 3D space.
By combining the mutational data in the Catalogue of Somatic Mutations in Cancer (COSMIC) and
the spatial information in the Protein Data Bank (PDB), SpacePAC is able to identify novel mutation
clusters in many proteins such as FGFR3 and CHRM2. In addition, SpacePAC is better able to localize
the most significant mutational hotspots as demonstrated in the cases of BRAF and ALK. The R package
is available on Bioconductor at: http://www.bioconductor.org/packages/release/bioc/html/SpacePAC.
html.
Conclusion: SpacePAC adds a valuable tool to the identification of mutational clusters while considering
protein tertiary structure.
1 Background
Cancer, at its most basic, is caused by the accrual of somatic mutations within oncogenes and tumor sup-
pressors in the genome (Vogelstein and Kinzler, 2004). While mutations within tumor suppressors usually
lower or completely disrupt the activity of genes that promote cell apoptosis or regulate the cell cycle,
oncogenic mutations typically increase or destabilize the resulting protein output. As it is easier to dis-
rupt protein function than restore it, there has been significant pharmacological research geared towards
inhibiting oncogenic mutations as described in Faivre et al. (2006); Hartmann et al. (2009) and Moreau
et al. (2012). Coupled with the idea of “oncogene addiction”, that a small set of “driver” genes promote
uncontrolled cellular growth in a wide variety of cancers and that inactivation of these genes can significantly
impair tumorigenesis (Greenman et al., 2007; Weinstein and Joe, 2006), the identification of driver oncogenic
mutations has become of key importance due to its potential translational benefit.
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Due to the biological importance of this problem, a variety of methodologies have been proposed to
identify regions where activating mutations may occur. One approach is based on the idea that compared to
the background mutation rate, driver mutations will have a higher frequency of non-synonymous mutations
(Sjblom et al., 2006; Bardelli et al., 2003). Several improvements to this approach have been made such as
normalizing for gene length (Wang, 2002) as well as accounting for different mutation rates due to features
such as transitions versus transversions, location of CpG sites and tumor type (Youn and Simon, 2010).
Relatedly, instead of comparing the mutational frequency directly to the background rate, one can also com-
pare the ratio of nonsynonymous (Ka) to synonymous (Ks) mutations per site (Kreitman, 2000). Recently,
Bardelli et al. (2003); Lynch et al. (2004); Greenman et al. (2007) and Torkamani and Schork (2008) showed
that somatic mutations appear to cluster within protein kinases while Wagner (2007) and Zhou et al. (2008)
demonstrated that mutational clustering can be a sign of positive selection for protein function and thus
sites for protein engineering.
Alternatively, several machine learning methods have been developed to determine the nature of a spe-
cific mutation. For instance, Polyphen-2 (Adzhubei et al., 2010) attempts to discern whether a mutation
is deleterious while CHASM (Carter et al., 2009) attempts to distinguish between driver and passenger
mutations. These methods use a wide range of sequence and non-sequence features to build a set of rules
that are then used to score each mutation with the score value determining the mutation classification. The
rules are developed on a training data set via a variety of methods such as Random Forests (Breiman, 2001),
Bayesian Networks (Friedman et al., 1997) and Support Vector Machines (Cortes and Vapnik, 1995). The
features used often include information on the size and polarity of the substituted and original residues,
available structural information as well as evolutionary conservation (Reva et al., 2011). Some classifiers are
optimized to use only a small set of features in prediction. For example, the SIFT classifier (Ng and Henikoff,
2001), only uses evolutionary conservation to predict whether the protein functional change is tolerated or
damaging.
While all these methods have shown some success in identifying damaging or deleterious mutations, they
nevertheless have limitations. Methods that rely upon differentiating the frequency of synonymous and
non-synonymous mutations as compared to the background rate may fail to take into account that selection
may occur upon only a small region of the gene and that signal loss may occur when the gene is considered
in total. The methodologies proposed by Wang (2002) and Kreitman (2000) fail to distinguish between
activating and non-activating non-synonymous mutations while the method developed by Youn and Simon
(2010) may be biased if the background mutational rate is not accurately estimated. Furthermore, not only
do machine learning classifiers require several sources of information that need to be periodically updated
to account for new research, it is often the case that much of the requisite information needs to be collected
for the first time at significant expense.
Building upon the hypothesis that driver mutations tend to cluster in functionally relevant protein re-
gions, Ye et al. (2010); Ryslik et al. (2013a) and Ryslik et al. (2013b) recently developed several statistical
methodologies to identify mutational clusters. Specifically, Ye et al. (2010) developed Non-Random Mu-
tational Clustering (NMC ) which identifies mutational clusters by testing against the null hypothesis that
missense substitutions follow a uniform distribution. iPAC (Ryslik et al., 2013a) and GraphPAC (Ryslik
et al., 2013b) expanded upon NMC by taking into account protein tertiary structure via a MultiDimensional
Scaling approach (MDS) (Borg and Groenen, 1997) and a graph theoretical approach, respectively. While
both of these methods improved over the linear NMC method, they nevertheless remap the protein to one
dimensional space resulting in information loss.
In this article, we provide an improvement to iPAC , GraphPAC and NMC by considering the protein
directly in three dimensional space and thereby avoid the information loss inherent in dimension reduction
algorithms. Using this new approach, we identify the most number of proteins with significant clusters at
the same false discovery rate, including proteins, such as FGFR3 and CHRM2, whose clusters are missed
by iPAC , GraphPAC and NMC (see Section 3.1). In addition, SpacePAC provides better “localization”
for mutational hotspots (see Section 3.2). Finally, we show that many of the mutational hotspots identified
by SpacePAC are categorized as activating mutations by CHASM and damaging mutations by PolyPhen-2.
Overall, by avoiding the protein remapping step required by iPAC and GraphPAC as well as the multiple
comparison penalty these methods incur for looking at every pairwise combination of mutations, we are
better able to identify mutational hotspots that are indicative of driver mutations. For the rest of this
paper, we refer to the set of NMC , GraphPAC , and iPAC as the “pairwise methods” as they consider every
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pairwise combination at the cost of an extra multiple comparison adjustment.
2 Methods
SpacePAC uses a three step process to identify mutational clusters. Step one is to obtain the mutational
and structural data (see Sections 2.1 and 2.2). Step two is to reconcile the databases so that the mutational
information can be mapped onto the protein structure (see Section 2.3). The third step is to simulate
the distribution of mutation locations over the protein tertiary structure and identify if any regions of the
protein have observed mutational counts in the tail of the distribution (see Section 2.4). Finally, although not
part of the SpacePAC algorithm, we perform a multiple comparison adjustment to account for the multiple
structures considered (see Section 2.6).
2.1 Obtaining Mutational Data
The 65th version of the COSMIC SQL database, the latest version as of when this paper was written,
was used to obtain the mutation data. First, only missense substitution mutations recorded as “confirmed
somatic variant” or “Reported in another cancer sample as somatic” were used. Further as both SpacePAC
and the pairwise methods are tested against the null hypothesis that mutations are randomly distributed
along the protein, only mutations from whole gene or whole genome screens were retained in order to avoid
selection bias. Next, only genes labeled with a Uniprot Accession Number (Consortium, 2011) were kept
as the Uniprot identification was used to match the protein sequence to the protein structure. Finally, as
several studies may report mutational data from a single cell line, mutation duplications were removed in
order to avoid over counting specific mutations (see “COSMIC Query” in the supplementary materials for
the SQL code).
2.2 Obtaining 3D Structural Data
Protein structures were obtained from the PDB. The spatial coordinates of the α-carbon atom in each amino
acid were used to represent that amino acid’s location in 3D space. Further, as multiple structures are often
available for the same protein, all structures that matched the protein’s UniProt Accession Number were
analyzed and an appropriate multiple comparison adjustment applied afterwards (see Section 2.6). If multiple
polypeptide chains within the same structure matched the Uniprot Accession Number, the first matching
chain shown in the file was used (commonly chain “A”). Similarly, if the structure resolution provided more
than one protein conformation, the first conformation listed in the pdb file was kept. For a full listing of the
1,903 structure/side-chain combinations considered, see “Structure Files” in the supplementary materials.
2.3 Reconciling Structural and Mutational Data
As the residue numbering scheme often differs between the COSMIC and PDB databases, we reconciled the
information in both sources. Similar to iPAC and GraphPAC , SpacePAC provides the user two possible
reconciliation options. The first option is based upon a numerical reconstruction from the structural data
available directly in the PDB file while the second performs a pairwise alignment as detailed in Pages et al.
(2012). As the PDB file structure may change depending upon when the file was added to the database
along with other technical difficulties, we used pairwise alignment to reconcile the mutational and positional
information for each structure unless specifically noted. For further information on the pairwise alignmnent,
please see the iPAC package available on Bioconductor. Successful alignment was obtained for 131 proteins
corresponding to 1,110 individual structure/side-chain combinations. Note that structures that did not have
tertiary data on at least two mutations were considered blank (as no clustering is possible) and dropped
from the analysis. See “Structure Files” in the supplementary materials for full details of each combination.
2.4 Identifying Mutational Hotspots
The general principle for SpacePAC is that we identify the one, two and three non-overlapping spheres that
cover as many of the mutations as possible at various radii lengths. We then normalize the number of
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mutations covered by the spheres and find the maximum normalized value. This value is then compared to
a simulated distribution to obtain a p-value. Specifically, we proceed as follows:
• Let s be the number of spheres we consider. s ∈ {1, 2, 3}.
• Let r be the radius considered. Here we consider, r ∈ {1, 2, 3, 4, 5, 6, 7, 8, 9, 10}.
• Simulate T (≥ 1000) distributions of mutation locations over the protein structure. For each simulation,
the mutations are randomly permuted among all the amino acids.
Next, let X0,s,r represent the number of mutations captured by the s spheres. If s = 3, we iden-
tify the sphere centers, p1, p2, p3, in such a way such that the spheres capture as many of the total mu-
tations as possible (See Section 2.5). Let Xi,s,r represent the same statistic but for simulation i. For
given {s, r}, calculate µs,r = mean
1≤i≤T
{Xi,s,r} and σs,r = std.dev.
1≤i≤T
{Xi,s,r}. For each simulation, calculate
Zi = maxi{(Xi,s,r − µs,r)/σs,r}. The p-value is then estimated as: (
∑
1Z0>Zi)/T . Note that while we
identify up to three spheres (or “hotspots”) that contain mutational clustering, only one p-value is necessary
to reflect the statistical significance of all the hotspots. This process is best seen through Figure 1. For the
rest of this paper, we will refer to “hotspot” and “cluster” interchangeably.
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Figure 1: In this example, we consider r ∈ {3, 9} and up to 3 potential mutational hotspots in the protein. First, µ and σ
are calculated over each column. Next, we normalize each entry in the column by calculating Zi,s,r =
Xi,s,r−µs,r
σs,r
. We then
take the maximum over each row to get Z0, ..., Z1000. The percentage of times Z0 ≥ Zi, where i ∈ {1, ..., 1000}, is the p-value
of our observed statistic Z0. Note that if Z0 is less than Zi for all 1000 simulations, we report a p-value of <1.00 E-03.
2.5 Algorithm for identifying sphere positions
In the approach described in Section 2.4, we find the 1, 2 and 3 non-overlapping spheres that cover the most
mutations given a pre-specified radius length. Ignoring sphere overlap for the moment, if only one sphere is
considered, the number of possible spheres is linear in the length of the protein (namely, a sphere centered
at each residue). If two spheres are considered, there are
(
N
2
)
possible sphere combinations if the protein
is N residues long. Similarly, if three spheres are considered, there are
(
N
3
)
such combinations (once again
ignoring sphere overlap). For a medium-sized protein like PIK3Cα which is 1,068 residues long, considering
three spheres allows for
(
1,068
3
)
= 202, 461, 116 possible positions. This makes it prohibitively expensive to
perform a brute force approach. To quickly find the best sphere orientation, we execute Algorithm 1 below.
Algorithm 1 is presented for 2 spheres but is trivially extendable to 3 or more spheres as well.
To help illustrate this algorithm, consider a proteinN residues long with five mutated amino acid positions
and suppose that we are interested in finding the two spheres that capture the most mutations. Without
loss of generality and for ease of exposition, number the mutated residues 1 through 5. Further, assign the
following mutation counts to these residues: residue 1 - 50 mutations, residue 2 - 40 mutations, residue 3 - 30
mutations, residue 4 - 20 mutations and residue 5 - 10 mutations. For clarity, we assume that the mutation
counts are unique, but the algorithm is unaffected if there are identical mutation counts for some residues.
We first construct the table shown in Figure 2, where the inside of the matrix is calculated to be the sum of
4
Algorithm 1 We are interested in finding the two non-overlapping spheres that contain the most mutations.
The algorithm takes as input a sorted vector v of mutation counts per amino acid where the amino acids
are sorted from largest to smallest by mutation count. Amino acids with no mutations are not included in
v. Note that the “cand” variable is an ordered list of 3-tuples.
Require: Sorted vector of counts v with length >= 2
starti = 2;
startj = 1;
k = length(v);
cand = [(starti, startj,v[starti] + v[startj])]
while (!is.empty(cand)) do
index = max(cand) {#Max over the 3rd element in the 3-tuple.}
i,j,s = cand[index]
cand = cand[-index] {#Removes the current max.}
if (No overlap between sphere i and j) then
Return (i, j, v[i]+v[j]) {#Successful combination found.}
end if
if (j ==1) and (i < k) then
cand.append[(i+1, j,v[i+1] + v[j])]
end if
if (j + 1 < i) then
cand.append[(i, j+1,v[i] + v[j+1])]
end if
end while
Return NULL {#No succesful combination found.}
the number of mutations at amino acid i and amino acid j. Observing, that the table is symmetric, we only
need to evaluate the residues below the diagonal as the entries on the diagonal originate from residues that
overlap each other perfectly. Thus for entry (i, j) we are considering two spheres, one centered at residue i
and one centered at residue j.
1 2 3 4 5
Counts 50 40 30 20 10
1 50 100 90 80 70 60
2 40 90 80 70 60 50
3 30 80 70 60 50 40
4 20 70 60 50 40 30
5 10 60 50 40 30 20
Figure 2: In our example, the protein has 5 residues with mutations. The residues are sorted from largest to smallest (so
residue 1 has the largest number of mutations, residue 2 the second largest number of mutations, etc.), and the inside of the
table is calculated as the sum of the mutations on both residues. In the actual code, only the lower half of the table is considered
and then only sequentially to decrease running time, but we present the whole table here for clarity.
The algorithm proceeds by appending to the “candidate” stack the element directly below and the
element directly to the right starting from the (2,1) entry. An “element” consists of a 3-tuple (i, j, s) where
i represents the row, j represents the column and s represents the value in position (i, j). After every two
potential appends to the stack, the maximum value over the 3rd position is found (with the third position
corresponding to the number of mutations covered by both spheres). The two spheres that contribute to
this max element are then checked for overlap. If the spheres do not overlap, then a successful case has
been found and the algorithm completes. If the spheres do overlap, the next set of elements are appended
and the process continues. By proceeding in the way described in Algorithm 1, at each iteration, the pair
of spheres being considered contain the maximum number of mutations possible from the remaining set of
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sphere combinations. Hence, once the first pair of non-overlapping spheres is found, the optimal sphere
combination has been found and the algorithm can terminate. To see this process, see Figure 3.
Figure 3: This figure refers to the data in Figure 2. The first index, i, represents the row and the second index, j, represents
the column. The third index, s, represents the total number of mutations at amino acids i and j. Beginning in position (2,1,90),
we then add (3,1,80) to the list, then {(4,1,70), (3,2,70)} and so forth. After each addition to the list, we pick the element with
the highest value in the third position of the 3-tuple.
2.6 Multiple Comparison Adjustment For Structures
A multiple comparison adjustment was performed to account for testing 1,110 protein structures. Since many
structures may pertain to one protein, a Bonferroni adjustment is too conservative and an FDR approach
was used. Specifically, a rough FDR (rFDR) (Gong et al., 2009) approach, which is a good approximation
to the standard FDR approach (Benjamini and Hochberg, 1995) when there are a large number of positively
correlated or independent tests, was applied. In our case, the cutoff is set at:
rFDR = α
(
k + 1
2k
)
where k = 1, 110, the total number of structures in the study. Using an α = 0.05, the rFDR ≈ 0.025023.
To be conservative, we rounded down and deemed all clusters with a p-value less than or equal to 0.025 to
be significant.
3 Results and discussion
Of the 131 proteins considered, SpacePAC identified 18 proteins with significant clustering as shown in
Table 1. For a full list of which structures were found significant under SpacePAC , GraphPAC and NMC ,
see “Results Summary” in the Supplementary materials. We note that while Table 1 shows the p-values for
the 18 proteins found significant by SpacePAC , there were 5 proteins that were found significant only by
GraphPAC , 1 protein only by iPAC and 1 protein only by NMC (see “Results Table” in the supplementary
materials for a complete list of what proteins were identified significant under each method). However, we
also note that SpacePAC identified the largest number of proteins with significant clustering at the same
false positive threshold1. We further note that several of the proteins identified only by SpacePAC have
already been associated with cancer as shown in Section 3.1. Furthermore, as shown in Figure 4, 14 out of
the 18 proteins identified by SpacePAC have their most significant hotspot overlap a biologically relevant
region and three of the remaining four proteins (CTNNB1, FGFR3 and FSHR) have been implicated with
cancer.
1The GraphPAC algorithm was run using each of the three insertion methods described in (Ryslik et al., 2013b). While the
methodology is the same, the nature of the algorithm leads to different results when different insertion methods are considered.
SpacePAC outperformed GraphPAC in comparison to each of the individual insertion methods.
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Method
Gene SpacePAC iPAC GraphPAC NMC
AKT1 <1.00 E-03 4.48 E-04 5.54 E-04 5.55 E-04
ALK <1.00 E-03 1.99 E-42 3.89 E-35 2.16 E-21
BRAF <1.00 E-03 <2.23 E-308 <2.23 E-308 <2.23 E-308
CHRM2 1.10 E-02
CTNNB1 2.00 E-03 6.69 E-03 1.09 E-03 1.09 E-03
DOCK2 2.20 E-02 9.29 E-03 3.39 E-03
FGFR3 2.00 E-02
FSHR 2.20 E-02
HRAS <1.00 E-3 1.55 E-23 1.87 E-32 2.68 E-15
IDE 2.00 E-02 3.60 E-03
IGF2R 1.40 E-02 3.06 E-03 9.04 E-03
KIF18A 6.00 E-03 1.56 E-02 1.56 E-02 1.56 E-02
KRAS <1.00 E-03 <2.23 E-308 <2.23 E-308 <2.23 E-308
NRAS <1.00 E-03 1.53 E-75 6.65 E-77 6.77 E-77
PIK3CA <1.00 E-03 4.73 E-118 4.73 E-118 4.73 E-118
PTEN <1.00 E-03 5.71 E-03 7.60 E-04 1.68 E-04
SEC23A 1.70 E-02 1.18 E-02
TP53 <1.00 E-3 1.78 E-134 6.22 E-169 1.08 E-88
Table 1: This table shows the p-value of the most significant cluster for each of the 18 proteins identified by SpacePAC as
well as the corresponding p-value under iPAC , GraphPAC and NMC . A blank entry in position (i, j) signifies that methodology
j did not find any structures with significant clustering for protein i. Note that given ni total mutations for protein i, the
pairwise methodologies perform
ni(ni−1)
2
comparisons, one for each pair of mutations. As such, the p-values shown for iPAC ,
GraphPAC and NMC have been multiplied by
ni(ni−1)
2
in order to account for the multiple comparison and provide a number
directly comparable to the SpacePAC p-value. Also, while the GraphPAC methodology was run under all three insertion
methods (Cheapest, Nearest and Farthest) as described by (Ryslik et al., 2013b), we display the minimum p-value over the
three methods.
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Figure 4: A breakout of what biologically relevant regions are overlapped by the most significant cluster for each of the 18
proteins. Overall, 77% of the hotspots overlap a binding site or a protein domain. For a full description regarding the overlap
between SpacePAC identified hotspots and structurally significant regions, see “Relevant Sites” in the supplementary materials.
Specifically, for CTNNB1, the SpacePAC identified hotspot covers mutations G34R and G34V, which
are associated with hepatocellular carcinoma and hepatoblastoma (Legoix et al., 1999; Koch et al., 1999),
respectively. Further, FSHR has been shown to be expressed in the vascular endothelial tissue of a wide
range of human tumors including lung, breast, prostate, colon and leiomyosarcoma (Siraj et al., 2013). For
more detail on FGFR3, see Section 3.1.
Finally, we evaluated SpacePAC performance via two common machine learning methods, PolyPhen-2
(Adzhubei et al., 2010) and CHASM (Carter et al., 2009). Before we summarize the results, we note that
PolyPhen-2 and CHASM utilize a large set of features when evaluating each mutation. The advantage of
SpacePAC is that it is able to be run with vastly less a priori information. Out of the 38 mutated amino acids
that fall within SpacePAC identified hotspots, PolyPhen-2 identifies 36 (95%) as damaging while CHASM
identifies 31 (82%) as driver mutations at a FDR of 20%. On the protein level, PolyPhen-2 identifies all
the 18 proteins identified by SpacePAC as significant while CHASM identifies 14 proteins as significant.
Moreover, SpacePAC identifies several proteins with significant clustering that are missed by the machine
learning methods. For instance, SpacePAC identifies FSHR as significant, which, as described above, has
recently been associated with cancer. However, CHASM calculates a FDR of 0.45 for FSHR, which is
above the significance threshold. See “Performance Evaluation” in the supplementary materials for more
information.
3.1 SpacePAC finds novel proteins
As described in Section 3, SpacePAC identified three novel proteins that were missed by NMC , iPAC and
GraphPAC . We will now consider two of these proteins, Fibroblast Growth Factor Receptor 3 (FGFR3), and
Muscarinic Acetylcholine Receptor M2 (CHRM2 or M2).
The CHRM2 structure (PDB ID: 3UON) (Haga et al., 2012) was identified by SpacePAC as having two
significant mutational hotspots (p-value = 0.011) located at residues 52 and 144 (see Figure 5). CHRM2,
essential for the physiological regulation of cardiovascular function (Haga et al., 2012) has been implicated
in a variety of cardiovascular diseases. Recently, CHRM2 has also been associated with both autoimmune
diseases and cancer (Ockenga et al., 2013). Current research shows that M2 receptors are expressed in both
glioblastoma cell lines and human samples. Moreover, the M2 agonist arecaidine strongly decreases cell
proliferation in both primary cultures and cell lines in a dose and time dependent response profile. This
suggests that M2 activation has an important role in suppressing glioma cell proliferation and can provide
a novel therapeutic target (Ferretti et al., 2013). Had the spatial structure not been taken into account, as
under NMC , or if the structure was accounted for but only via remapping to 1D space, as under iPAC and
GraphPAC , this cluster would have been missed.
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Figure 5: The CHRM2 structure (PDB ID: 3UON) where residues 52 and 144 are highlighted.
SpacePAC identified the FGFR3 structure (PDB ID: 1RY7) (Olsen, 2004) as having one significant
hotspot (p-value = 0.020) centered at amino acid 248 (see Figure 6). FGFR3 is a tyrosine-protein kinase
which plays a critical role in regulating cell differentiation, proliferation and apoptosis and is often associated
with cancer and developmental disorders (Hart et al., 2001). Mutation R248C occurs in the Ig-like domain
and is a severe and lethal mutation associated with bladder cancer (Hadari and Schlessinger, 2009) along
with a variety of other phenotypes such as thanatophoric dwarfism (Rousseau, 1996) and epidermal nevi
(Hafner, 2006). This cluster represents a perfect example of signal loss when all pairwise mutations are
considered. In the case of our data, as all the mutations occur on one residue, a cluster is formed at that one
residue only. There is therefore no difference between any of the pairwise methods as the remapping step has
no effect. However, since iPAC , GraphPAC and NMC need to account for all pairwise comparisons between
mutations (all occurring on residue 248), the signal is lost under all three methods. On the other hand, as
SpacePAC does not need to perform such a correction, it is successfully able to detect the cluster. Moreover,
we note that Qing et al. (2009) recently developed an anti-FGFR3 monoclonal antibody that interferes with
FGFR3 binding and inhibits R248C (Hadari and Schlessinger, 2009).
Figure 6: The FGFR3 structure (PDB ID: 1RY7) where residue 248 is highlighted blue.
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3.2 SpacePAC improves cluster localization
For protein-structure combinations in which mutational clusters are detected by other methods, SpacePAC
is often able to provide a smaller set of clusters compared to the pairwise methods while still covering the
majority of mutations. To illustrate this point we consider two examples, the BRAF structure (PDB ID:
3Q96) (Gould et al., 2011) where SpacePAC identifies 3 mutational hotspots and the ALK structure (PDB
ID: 2XBA) (Bossi et al., 2010) where SpacePAC identifies 2 mutational hotspots.
BRAF is a well known oncogene that is part of the RAS-RAF-MEK-ERK-MAP kinase pathway which is
often activated in human tumors. Further, it is estimated that approximately 90% of mutations in this gene
are a substitution of a glutamate for a valine at residue 600 (V600E) (Tan et al., 2008). In our mtuational
data, 187 (83.5%) mutations were on residue 600 with the remaining 37 mutations spread over 13 other
residues. Mutations on V600 typically result in constitutively elevated kinase activity and have been found
in a wide range of cancers such as metastatic melanoma, ovarian carcinoma and colorectal carcinoma (Davies
et al., 2002; Rajagopalan et al., 2002; Hingorani et al., 2003; Sjblom et al., 2006; Greenman et al., 2007;
Andreu-Prez et al., 2011). Due to the large number of V600 mutations, SpacePAC and all the pairwise meth-
ods identified residue 600 as the most significant “cluster” in all structures where tertiary information was
available on that residue. It is worth noting that BRAF V600 inhibitors, such as Vemurafenib, have already
been developed, further supporting the hypothesis that mutational clusters may represent pharmaceutical
targets (Mao et al., 2012).
As the signal presented by V600 is so strong, it may mask the signal from other mutations within the
BRAF protein. As such, we considered structure 3Q96 which does not have tertiary information for residues
600 and 601. Of the remaining 28 mutations spread over 12 residues, SpacePAC identifies three hot spots
with 7-8 mutations per cluster as shown in Table 2 (combined hot spot p-value <1.00 E-03). Moreover,
each of the three regions identified has been associated with oncogenic elevated kinase activity as well as a
variety of cancers such as lung adenocarcinoma, melanoma, colorectal adenocarcinoma and ovarian serous
carcinoma (Davies et al., 2002; Lee et al., 2003; Greenman et al., 2007).
Hotspot Center Within Sphere # Mutations
A 465 (464, 465, 466) 8
B 470 (469, 470, 471) 7
C 596 (595, 596, 597) 7
Table 2: The three hot spots identified by SpacePAC for the BRAF structure (PDB ID: 3Q96) at an optimal radius of 4A˚.
See Figure 7 for a visual orientation.
Together, the three hotspots identified by SpacePAC cover 79% of the mutations for which tertiary infor-
mation is available. Moreoever, while NMC , iPAC and the three GraphPAC methods report approximately
8 to 16 times as many clusters as SpacePAC (see Table 4), the additional clusters only cover the remaining
21% of mutations. Finally, all the residues that do not fall within SpacePAC hot spots are those which
have only one mutation. These additional clusters stem from the fact that NMC , iPAC and GraphPAC
must consider every pairwise combination of mutations resulting in many clusters that only differ from each
other by a few residues. Further, by considering every pairwise combination, many smaller clusters are often
combined into larger clusters with a less significant p-value. While technically still a “significant” cluster,
these extra clusters provide little additional information. As SpacePAC does not have to consider every
combination, it does not suffer from this issue.
We now consider the Anaplastic Lymphoma Kinase (ALK) protein for which SpacePAC identifies two
mutational hotspots (combined hot spot p-value <0.001) (see Table 3). The ALK protein is a receptor-
type tyrosine kinase that is preferentially expressed in neurons during the late embryonic stages (Motegi,
2004). Mutations in this protein have been associated with both neuroblastoma as well as non-small cell
lung cancer (Bang, 2012; George et al., 2008). Hotspots A and B in Table 3 both occur in the protein kinase.
Further, mutations on F1174 and R1275 can cause constitutive activation which impairs receptor trafficking
(Mazot et al., 2011). We note that SpacePAC perfectly identifies both hotspot locations. Moreover, it
has recently been shown that activating mutations F1174L and R1275Q provide therapeutic targets in
neuroblastoma (George et al., 2008), supporting the hypothesis that mutational clusters are indicative of
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Figure 7: The BRAF structure (PDB ID: 3Q96) where cluster 464-466 is shown in blue, 469-471 is shown in red and 595-597
is shown in purple. The central residue in each cluster (465, 470 and 596 for the blue, red and purple clusters respectively) is
labeled.
activating mutations.
Hotspot Center Within Sphere # Mutations
A 1174 (1173, 1174, 1175) 11
B 1275 (1274, 1275, 1276) 12
Table 3: The two hot spots identified by SpacePAC as significant for the ALK Structure (PDB ID: 2XBA) (Bossi et al.,
2010) at an optimal radius of 4A˚. See Figure 8 for a visual orientation.
The two hotspots identified by SpacePAC cover 88.5% of all the mutations in our data with the remaining
mutations occurring on residues with only one mutation each. Further, as seen in Table 4, the pairwise
methods have 3 to 5.5 times as many clusters as SpacePAC . As before, by not having to consider every
pairwise combination and thus not reporting similar clusters, SpacePAC is able to better localize the critical
mutational areas.
Figure 8: The ALK structure (PDB ID: 2XBA) where cluster 1173-1175 is shown in blue and cluster 1274-1276 is shown in
red. The central residue in each cluster (1174 and 1275 for the blue and red clusters respectively) is labeled.
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# Clusters/Hotspots
Method/ Protein-Structure BRAF - 3Q96 ALK-2XBA
SpacePAC 3 2
NMC 22 11
iPAC 45 11
GraphPAC -Cheapest 36 7
GraphPAC -Nearest 45 8
GraphPAC -Farthest 47 6
Table 4: The number of clusters found under each method. As SpacePAC does not need to consider every pairwise
combination of mutations, the method provides a much smaller number of potential hotspots while still covering the majority
of mutations.
4 Conclusion
In this article we provide a novel algorithm to account for protein tertiary structure when identifying mu-
tational clusters in proteins. By considering the protein structure directly in 3D space, we avoid the use of
a dimension reduction algorithm and potential information loss. Further, by not considering every pair of
mutations, we are able to reduce the multiple comparison penalty and identify additional clusters. We show
several examples of clusters that are not identified by alternative methods as well as the ability to improve
cluster localization while still covering the majority of mutations. Moreover, several of our examples iden-
tified clusters which overlap potential therapeutic targets, supporting the hypothesis that clusters may be
indicative of activating driver mutations. Finally, since the SpacePAC methodology does not need to look at
every pairwise combination of mutations it also runs much faster for proteins with many (> 400) mutations.
In these situations, while the pairwise methods may take several days to complete, SpacePAC still finishes
in a matter of hours. For proteins with fewer mutations, the running time of all the pairwise methods as
well as SpacePAC is comparable, with the majority of protein/structure combinations terminating in under
10 minutes when executed on a consumer desktop with an Intel i7-2600k processor (at a frequency of 3.40
GHZ) and 16 GB of DDR3 RAM.
SpacePAC , while presenting an important alternative to the one dimensionality restriction required by
iPAC and GraphPAC , is nonetheless subject to several limitations. First, SpacePAC is currently limited
to at most three mutational hotspots to save on computational time. While it is unlikely that a single
structure will have more than three hotspots, the extension to allow SpacePAC to account for more than three
hotspots is algorithmically simple. As SpacePAC was able to process our entire database of protein/structure
combinations in under 5 hours (with all the structures evaluated in parallel), this restriction is minimal and
will only grow smaller as computational power increases.
Second, to satisfy the uniformity assumption, the mutational status of each amino acid must be known.
However, due to improvements in high-throughput sequencing, this is rapidly becoming a non-issue. Next,
unequal rates of mutagenesis in specific genomic regions may violate the assumption that each residue has
an equal probability of mutation. To help ensure that our data met this statistical assumption, we only
considered missense mutations as many insertion and deletion mutations are sequence dependent. Relatedly,
while the literature shows that CpG dinucleotides often have a mutational rate ten times or higher when
compared to other locations (Sved and Bird, 1990), approximately only 14% of the clusters presented in
section 3.1 and 3.2 overlapped CpG sites. Similarly, cigarette use typically causes transversion mutations
within lung carcinomas (Ye et al., 2010) while colorectal carcinomas result in transition mutations (Hollstein
et al., 1991). In the case of KRAS however, the vast majority of mutations are located on residues 12, 13 and
61 for both cancers. This signifies that while the mutational type may differ, the impact on mutation location
is minimal and does not violate the uniformity assumption. Lastly, it is worth noting that as we obtained
our mutational data from the COSMIC database, specific tissue types may be more represented than others.
However, under this situation our analysis would be more conservative and the resulting findings even more
significant as explained below. Aggregating over all tissues increases the total number of mutations, thus
increasing the number of simulated mutations within any given segment of the protein. The resulting p-value
of any observed hotspot would lose significance as more mutations would be simulated within the cluster.
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Overall, while this as well as previous studies are impacted by several external factors, it appears that
selection of the cancer phenotype is the primary cause of clustering.
In conclusion, SpacePAC presents a novel approach to account for protein tertiary structure when identi-
fying mutational hotspots. We show that SpacePAC identifies novel clusters of biological relevance, improves
cluster localization and in several cases identifies pharmaceutical targets for which therapies are already in
production. In turn, we further confirm the hypothesis that mutational hotspots are indicative of driver
mutations and show that SpacePAC can be used to quickly locate such potential mutations as additional
structures are published.
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